Abstract
Mycolic acids are the major lipid components of the unique mycobacterial cell wall responsible for the protection of the tuberculosis bacilli from many outside threats. Mycolic acids are synthesized in the cytoplasm and transported to the outer membrane as trehalose- containing glycolipids before being esterified to the arabinogalactan portion of the cell wall and outer membrane glycolipids. The large size of these unique fatty acids is a result of a huge metabolic investment that has been evolutionarily conserved, indicating the importance of these lipids to the mycobacterial cellular survival. There are many key enzymes involved in the mycolic acid biosynthetic pathway, including fatty acid synthesis (KasA, KasB, MabA, InhA, HadABC), mycolic acid modifying enzymes (SAM-dependent methyltransferases, aNAT), fatty acid activating and condensing enzymes (FadD32, Acc, Pks13), transporters (MmpL3) and tranferases (Antigen 85A-C) all of which are excellent potential drug targets. Not surprisingly, in recent years many new compounds have been reported to inhibit specific portions of this pathway, discovered through both phenotypic screening and target enzyme screening. In this review, we analyze the new and emerging inhibitors of this pathway discovered in the post-genomic era of tuberculosis drug discovery, several of which show great promise as selective tuberculosis therapeutics.
Keywords: Tuberculosis, antituberculosis agents, mycolic acid, fatty acid synthase, KasA, KasB, MabA, HadABC, InhA, FadD32, Pks13, MmpL3, antigen 85.
Current Pharmaceutical Design
Title:New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics
Volume: 20 Issue: 27
Author(s): E. Jeffrey North, Mary Jackson and Richard E. Lee
Affiliation:
Keywords: Tuberculosis, antituberculosis agents, mycolic acid, fatty acid synthase, KasA, KasB, MabA, HadABC, InhA, FadD32, Pks13, MmpL3, antigen 85.
Abstract: Mycolic acids are the major lipid components of the unique mycobacterial cell wall responsible for the protection of the tuberculosis bacilli from many outside threats. Mycolic acids are synthesized in the cytoplasm and transported to the outer membrane as trehalose- containing glycolipids before being esterified to the arabinogalactan portion of the cell wall and outer membrane glycolipids. The large size of these unique fatty acids is a result of a huge metabolic investment that has been evolutionarily conserved, indicating the importance of these lipids to the mycobacterial cellular survival. There are many key enzymes involved in the mycolic acid biosynthetic pathway, including fatty acid synthesis (KasA, KasB, MabA, InhA, HadABC), mycolic acid modifying enzymes (SAM-dependent methyltransferases, aNAT), fatty acid activating and condensing enzymes (FadD32, Acc, Pks13), transporters (MmpL3) and tranferases (Antigen 85A-C) all of which are excellent potential drug targets. Not surprisingly, in recent years many new compounds have been reported to inhibit specific portions of this pathway, discovered through both phenotypic screening and target enzyme screening. In this review, we analyze the new and emerging inhibitors of this pathway discovered in the post-genomic era of tuberculosis drug discovery, several of which show great promise as selective tuberculosis therapeutics.
Export Options
About this article
Cite this article as:
North Jeffrey E., Jackson Mary and Lee E. Richard, New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118203641
DOI https://dx.doi.org/10.2174/1381612819666131118203641 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Green and Sustainable Technology: Efficient Strategy for the Synthesis of
Biologically Active Pyrimidine Derivatives
Current Organocatalysis Visceral Leishmaniasis: Advances in Treatment
Recent Patents on Anti-Infective Drug Discovery Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Microwave-assisted Single Step Cinnamic Acid Derivatization and Evaluation for Cytotoxic Potential
Current Pharmaceutical Biotechnology Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Sulphur-Containing Heterocycles as Antimycobacterial Agents: Recent Advances in Thiophene and Thiadiazole Derivatives
Current Topics in Medicinal Chemistry Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Current Immunology Reviews (Discontinued) Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Recent Patents of Gene Sequences Relative to DNA Polymerases
Recent Patents on DNA & Gene Sequences Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research Improving DNA Vaccine Performance Through Vector Design
Current Gene Therapy Metabolism of the Antituberculosis Drug Ethionamide
Current Drug Metabolism Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Current Medicinal Chemistry Application of Multivariate Linear and Nonlinear Calibration and Classification Methods in Drug Design
Combinatorial Chemistry & High Throughput Screening Recent Patents and Advances on Anti - Tuberculosis Drug Delivery and Formulations
Recent Patents on Drug Delivery & Formulation Virtual Screening of Drugs: Score Functions, Docking, and Drug Design
Current Computer-Aided Drug Design Targeting Folate Metabolism in the Human Malaria Parasite Plasmodium falciparum
Current Enzyme Inhibition Anti-Bacterial Drug Discovery Using Systems Biology
Mini-Reviews in Medicinal Chemistry Vascular Wall-Related Biomarkers in Sepsis: A Review of Current Evidence and a Critical Appraisal of Recent Patents
Recent Patents on Biomarkers Impact of Cerebral Malaria on Brain Distribution of Mefloquine
Drug Metabolism Letters